BioSpace News Archive

GRAIL, LLC, and AstraZeneca (LSE/STO/Nasdaq: AZN), today presented new data from a study assessing the feasibility of a pan-hematologic malignancy classifier (pan-heme classifier) based on GRAIL’s methylation platform as a potential tumor-agnostic, plasma-based cell free DNA minimal residual disease (MRD) test.

INVO Bioscience, Inc. (Nasdaq: INVO) (“INVO” or the “Company”) today announced financial results for the fourth quarter and fiscal year ended December 31, 2022 and provided a business update.

Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) announced that an abstract highlighting its lead drug candidate, rencofilstat, will be presented by its Chief Scientific Officer, Daren Ure, PhD, at the American Association for Cancer Research Annual Meeting, which is being held April 15-19, 2023, in Orlando, Florida.

BiondVax Pharmaceuticals Ltd. published its full-year financial results for the year ended December 31, 2022, and provided a business update.

NANOBIOTIX today announces it will issue its financial results for full-year ending December 31, 2022 and provide an operational update, on Monday, April 24, 2023, after the close of the US market.

Stevanato Group S.p.A. announced that it will issue financial results for the first quarter of 2023 on Thursday, May 4, 2023, at 6:30 a.m.

Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended March 31, 2023 before the market opens on April 25, 2023, and will hold a conference call to discuss the results at 9:00 a.m. Eastern Time.

Innoviva, Inc. today announced that the U.S. Food and Drug Administration’s (FDA) Antimicrobial Drugs Advisory Committee (AMDAC) unanimously voted 12-0 in support of approval based on a favorable benefit-risk assessment of sulbactam-durlobactam for the treatment of adults with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible strains of Acinetobacter baumannii-calcoaceticus complex (Acinetobacter).

Scientific Industries, Inc. reported financial results for the six-month transition period ended December 31, 2022, following its change in fiscal year end from June 30 to December 31.

AbbVie announced that the U.S. Food and Drug Administration has approved expanding the indication of QULIPTA® for the preventive treatment of migraine in adults.